文献速递前列腺增生与排尿功能障碍

α1受体阻滞剂联合5α还原酶抑制剂治疗下尿路症状提示良性前列腺增生患者中停用α1受体阻滞剂的效应:一项使用尿动力学的前瞻性对照试验

Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
PubMed 文献 · J Urol · 2017-05-10

140例下尿路症状提示良性前列腺增生的门诊患者先接受西洛多辛8 mg/日联合度他雄胺0.5 mg/日治疗12个月,其中132例随机分为继续联合治疗组或停用西洛多辛改为度他雄胺单药治疗组。结果显示两组主观症状与膀胱出口梗阻无显著差异,但单药组储尿功能下降,且体重指数较高者停药后下尿路症状显著恶化。作者认为停用α1受体阻滞剂合理且可耐受,但高体重指数患者需谨慎。

要点

  • 联合治疗12个月后停用α1受体阻滞剂,两组I-PSS变化分别为-0.7和-0.6,无显著差异。
  • 膀胱出口梗阻指数联合治疗组从46.1降至41.8,单药组从42.9降至39.9,两组无显著差异。
  • 单药组储尿功能下降,体重指数较高者停药后下尿路症状显著恶化。

核心结论

  • 停用α1受体阻滞剂对下尿路症状和膀胱出口梗阻的影响合理且可耐受,但高体重指数患者停药需谨慎。

研究设计与样本

  • 前瞻性对照试验:140例下尿路症状提示良性前列腺增生的门诊患者先接受西洛多辛8 mg/日联合度他雄胺0.5 mg/日治疗12个月,其中132例随机分为继续联合治疗组或停用西洛多辛改为度他雄胺单药治疗组,评估随机化前至随机化后12个月的参数变化。

主要发现

  • 疗效分析纳入联合治疗组57例和单药治疗组60例。
  • 随机化后I-PSS变化联合治疗组为-0.7,单药治疗组为-0.6。
  • 膀胱出口梗阻指数联合治疗组从46.1变为41.8,单药治疗组从42.9变为39.9。
  • 两组主观症状和膀胱出口梗阻无显著差异。
  • 单药治疗组储尿功能下降,体重指数较高的患者转为度他雄胺单药治疗后下尿路症状显著恶化。

临床怎么用

  • 作者认为从联合治疗中停用α1受体阻滞剂合理且可耐受,但高体重指数患者停药需谨慎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We compared the effects on lower urinary tract symptoms and bladder outlet obstruction of combination therapy with α1-blocker and 5α-reductase inhibitor or a switch to 5α-reductase inhibitor monotherapy. We determined the factors influencing changes in lower urinary tract symptoms after α1-blocker withdrawal. MATERIALS AND METHODS: A total of 140 outpatients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia received combination therapy with silodosin 8 mg per day and dutasteride 0.5 mg per day for 12 months. Of the patients 132 were randomized to continue combination therapy or switched to dutasteride monotherapy through silodosin withdrawal as the monotherapy group. Parameter changes from before randomization to 12 months after randomization were assessed based on subjective symptoms and urodynamic findings of voiding and storage function. RESULTS: Efficacy analysis included 57 patients on combination therapy and 60 on monotherapy. The change in I-PSS (International Prostate Symptom Score) after randomization was -0.7 and -0.6 in the combination therapy and monotherapy groups, respectively. The bladder outlet obstruction index changed from 46.1 to 41.8 in the combination therapy group and from 42.9 to 39.9 in the monotherapy group. No significant differences in subjective symptoms and bladder outlet obstruction were observed between the 2 groups. However, storage function decreased in the monotherapy group and lower urinary tract symptoms deteriorated significantly after the switch to dutasteride monotherapy in patients with a higher body mass index. CONCLUSIONS: We found that α1-blocker withdrawal from combination therapy was reasonable and tolerable with regard to the effect on lower urinary tract symptoms and bladder outlet obstruction. However, withdrawal must be performed carefully in patients with a high body mass index.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Matsukawa Y, Takai S, Funahashi Y, et al. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. J Urol. 2017. PMID: 28499730. doi:10.1016/j.juro.2017.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。